Functional and Patient-reported Outcomes following Transmetatarsal Amputation in High-risk Limb Salvage Patients

Romina Deldar, MD*
Gina Cach, BA†
Adaah A. Sayyed, BS**†
Brian N. Truong, BS†
Emily Kim, BS†
Jayson N. Arves, DPM‡
John S. Steinberg, DPM‡
Karen K. Evans, MD*
Christopher E. Attinger, MD*

Background: Transmetatarsal amputation (TMA) is performed in patients with nonhealing wounds of the foot. Compared with below-knee amputations, healing after TMA is less reliable, and often leads to subsequent higher-level amputation. The aim of this study was to evaluate the functional and patient-reported outcomes of TMA.

Methods: A retrospective review of patients who underwent TMA from 2013 to 2021 at our limb-salvage center was conducted. Primary outcomes included postoperative complications, secondary proximal lower extremity amputation, ambulatory status, and mortality. Univariate and multivariate analyses were performed to evaluate independent risk factors for higher-level amputation after TMA. Patient-reported outcome measures for functionality and pain were also obtained.

Results: A total of 146 patients were identified. TMA success was achieved in 105 patients (72%), and 41 patients (28%) required higher-level amputation (Lisfranc: 31.7%, Chopart: 22.0%, below-knee amputations: 43.9%). There was a higher incidence of postoperative infection in patients who subsequently required proximal amputation (39.0 versus 9.5%, \( P < 0.001 \)). At mean follow-up duration of 23.2 months (range, 0.7–97.6 months), limb salvage was achieved in 128 patients (87.7%) and 83% of patients (n = 121) were ambulatory. Patient-reported outcomes for functionality corresponded to a mean maximal function of 58.9%. Pain survey revealed that TMA failure patients had a significantly higher pain rating compared with TMA success patients (\( P = 0.016 \)).

Conclusions: TMA healing remains variable, and many patients will eventually require a secondary proximal amputation. Multi-institutional studies are warranted to identify perioperative risk factors for higher-level amputation and to further evaluate patient-reported outcomes. (Plast Reconstr Surg Glob Open 2022;10:e4350; doi: 10.1097/GOX.0000000000004350; Published online 25 May 2022.)

INTRODUCTION

Chronic foot ulcers affect up to 13% of the United States population, and the prevalence is rising as a result of an aging and increasingly comorbid population. Transmetatarsal amputation (TMA) is a limb salvage procedure for nonhealing forefoot pathologies. Current indications for a TMA include, but are not limited to, forefoot ulceration, ischemia, failed ray amputations, trauma, tumors, frostbite, and congenital deformities.

When successful, TMAs allow patients to maintain ambulation without a prosthesis, and at less energy expenditure than higher-level amputations. However, TMAs have variable healing rates, reportedly ranging from 28% to 78%, and are not without risk of complications. The large degree of variability in the reported rates of TMAs may be due to variations in how TMA success is defined. Some authors define “success” as closure of the wound, re-epithelialization of the wound, or when the stump is able to bear weight without a prosthesis.

Patients whose TMA wounds do not heal will require further operations, and up to one-third of TMAs will result in major amputation. Failed TMA can significantly burden patients and the healthcare system. Determining the degree to which patient comorbidities and surgical

Disclosure: The authors have no financial interest to declare in relation to the content of this article.
factors increase risk of failed TMA and secondary major lower extremity (LE) amputation may guide surgeons to initially perform the surgery with the best possible functional outcome for patients. However, the literature contains conflicting reports on factors associated with TMA failure. Thus, the primary aim of this study was to review our institution’s experience with TMA and to evaluate patient-reported outcomes in comorbid patients with chronic foot wounds.

**METHODS**

Following institutional review board approval, we performed a retrospective review of patients who underwent TMA from 2015 to 2021. TMA procedures were performed by authors of this study (J.N.A., J.S.S., C.E.A.). To identify independent predictors of secondary higher-level amputation after TMA, patients were stratified into successful TMA or higher-level amputation cohorts. For the purposes of this study, TMA failure was defined as the TMA sites that did not heal and required a more proximal amputation.

**Perioperative Management**

Preoperatively, patients were evaluated for medical comorbidities, and their LE wounds were serially debrided in the operating room. Their affected limb was evaluated by a vascular surgeon and they underwent LE endovascular angiography when indicated. The affected foot biomechanics were evaluated by podiatry and when indicated, correction was performed at the time of amputation. Between debridements, sterile negative-pressure wound therapy dressings were used to minimize wound contamination. Antibiotic administration was determined by foot wound culture sensitivities. Primary closure of the TMA wound was performed if there was adequate plantar and dorsal soft tissue for coverage without undue tension. Other closure methods consisted of local flaps (performed by authors C.E.A. and K.K.E.), or free tissue transfer (by K.K.E.). In cases of infection, open TMA with subsequent serial debridements was performed until the wound was considered ready for delayed primary closure. Additional procedures, including tendon Achilles lengthening or anterior tendon rebalancing, were performed to optimize functional results of TMA by preventing postoperative equinovarus deformity. Once healed, patients were fitted by podorthists or prosthetists for custom inserts with toe fillers to allow for ambulation in regular shoes.

**Retrospective Review**

Electronic medical records were reviewed to collect preoperative, intraoperative, and postoperative variables of interest. Preoperative data included patient demographics, comorbidities, wound conditions, and LE angiography findings. Intraoperative variables included TMA closure type and any additional procedures performed. Postoperative factors consisted of hospital length of stay, postoperative complications, TMA success, and long-term outcomes, such as higher-level amputation, limb salvage, ambulatory status at most recent follow-up, and mortality.

**RESULTS**

A total of 146 patients were identified. The majority of patients were men (n = 102, 70%). Average age and body mass index for the study population was 61.7 years and 28.7 kg per m², respectively. TMA success was achieved in 72%, whereas 28% required higher-level amputation. Postoperative infection was an independent predictor of higher-level amputation. Limb salvage and amputatory rates were 87.7% and 83%, respectively. Surveyed patients reported an average maximal function of 58.9%. TMA failure patients had a significantly higher pain rating compared with TMA success patients.

**Patient-reported Outcomes Measurements**

Phone surveys were conducted to collect patient-reported outcome measures in 2021. The Lower Extremity Functional Scales (LEFS) survey was used to assess patient-reported functional outcomes in our study population. Pain data were captured using three PROM scales. The 11-point Numerical Rating Scale (NRS) provided the gold standard for direct assessment of pain, scored from 0 (no pain) to 10 (worst pain). Patients were asked to report their current pain levels, and best and worst pain levels in the past 24 hours. To supplement this survey, two Patient-Reported Outcomes Measurement Information System (PROMIS) assessments were utilized: (1) Pain Intensity Short Form 3a, which measures current pain, average pain, and worst pain over the past 7 days, with higher t-scores indicating greater pain intensity, and (2) Pain Interference Short Form 8a, which measures the extent that pain interferes with the ability to participate in social, cognitive, emotional, physical and recreational activities over the past 7 days, with higher t-scores indicating greater pain interference. All surveyed patients provided verbal informed consent.

**Statistical Analyses**

Univariate analyses were performed with Student t-test, Mann-Whitney U-test, chi-squared test, or Fisher exact test based on statistical parameters. Multivariate regression analysis of significant univariate findings was then performed to identify independent risk factors for secondary proximal amputation after TMA. Odds ratios with 95% confidence intervals were calculated for each risk factor. Data analysis was performed using STATA, version 17.0 (StataCorp, College Station, Tex.), with statistical significance set at P values less than 0.05.

**Takeaways**

**Question:** What are the surgical and functional outcomes of transmetatarsal amputation (TMA)?

**Findings:** A retrospective review of 106 patients who underwent TMA was performed. TMA success was achieved in 72%, whereas 28% required higher-level amputation. Postoperative infection was an independent predictor of higher-level amputation. Limb salvage and ambulatory rates were 87.7% and 83%, respectively. Surveyed patients reported an average maximal function of 58.9%. TMA failure patients had a significantly higher pain rating compared with TMA success patients.

**Meaning:** TMA healing is variable, and many patients will eventually require a secondary proximal amputation.
no significant differences in comorbidities among TMA success and TMA failure patients. Similarly, preoperative nutrition labs and hemoglobin A1c levels were similar among the two cohorts. Osteomyelitis was significantly more prevalent in the TMA success group (61.0 versus 41.5%, \( P = 0.033 \)). On preoperative angiography, LE vessel runoff and endovascular intervention were similar between the two groups. Table 1 summarizes patient demographics, comorbidities, and preoperative testing for the study cohorts.

Table 2 compares surgical factors between the two groups. There were no differences in closure types among TMA success versus amputation patients. The prevalence of positive cultures on day of TMA closure was similar between those with TMA success and those who required a higher-level amputation (68.6% versus 70.7%, \( P = 0.946 \)). Additional procedures performed to treat or prevent equinovarus deformity were similar among the two groups, as well. Patients who required higher-level amputation had a significantly longer postoperative length of stay (22.5 versus 11.7 days, \( P = 0.002 \)). There was no difference in route of antibiotics administered on discharge between the groups.

Median time to higher-level amputation was 1.8 months (interquartile range, 0.6–6.2 months). There was a higher incidence of postoperative infection in patients who required more proximal amputation (39.0 versus 9.5%, \( P < 0.001 \)). Similarly, unplanned return to the operating room (82.9 versus 26.7%, \( P < 0.001 \)) occurred significantly more commonly in the higher-level amputees. Wound dehiscence was found to occur at higher rates in the higher-level amputee group, as well (56.1 versus 31.7%, \( P = 0.033 \)). Among the 41 patients who underwent higher-level amputation, Lisfranc amputation was performed in 13 patients (31.7%), Chopart amputation was performed in 9 patients (22.0%), and below-knee amputation (BKA) was performed in 18 patients (43.9%). At a mean follow-up duration of 23.2 months (range, 0.7–97.6 months), limb salvage was achieved in 128 patients (87.7%). At most recent follow-up, 83% of patients (\( n = 121 \)) were ambulatory. Forty-three patients (29.5%) had died. Table 3 summarizes the postoperative complications and long-term outcomes among TMA success and higher-level amputee groups. On multivariate regression analysis, postoperative infection (odds ratio: 4.39, \( P = 0.005 \)) was an independent predictor of TMA failure and subsequent proximal amputation (Table 4).

Of the 103 surviving patients, 46 patients (44.7%) completed LEFS surveys at a mean time from surgery of 38.7 months (SD 30.3). The mean LEFS score was 47.1 (SD 14.7), which corresponded to a mean maximal function of 58.9% (SD 18.4). When stratifying by patients who required higher-level amputation (\( n = 9 \)) versus those who did not (\( n = 37 \)), higher-level amputees trended toward having lower patient-reported functionality scores (39.1 versus 49.1, \( P = 0.068 \)) (Table 5).

Seventeen patients (16.5%) completed three pain surveys at an average time from surgery of 12.7 months (SD 13.9). Mean PROMIS pain interference \( t \)-score was 52.5 (SD 8.4) and pain intensity \( t \)-score was 50.4 (SD 10.7), with no significant difference in \( t \)-scores between higher-level amputee patients and those with TMA success. NRS pain scales found mean current pain of 1.8 (SD 2.2), best pain of 1.7 (SD 2.1) and worst pain of 2.8 (SD 2.7). Regarding NRS results, TMA failure patients had a significantly higher rating of current pain compared with TMA success patients (4.0 versus 1.1, \( P = 0.016 \)) (Table 6).

DISCUSSION

To our knowledge, this is the first study to compare patient-reported outcomes among patients with TMA success versus those who required higher-level amputation. TMA was originally described in 1855 by Bernard for treatment of trenchfoot.\(^{11}\) McKittrick et al then popularized TMA as a limb salvage procedure in 1949 for management of gangrene and diabetic forefoot infections.\(^{12}\) The

Table 1. Patient Demographics and Comorbidities

| Variable                        | Total (n = 146) | TMA Success (n = 105) | Higher-level Amputation (n = 41) | \( P \) |
|---------------------------------|----------------|-----------------------|---------------------------------|------|
| Men                             | 102 (69.9%)    | 78 (74.3%)            | 24 (58.5%)                      | 0.062|
| Age (y)                         | 61.7 ± 12.3    | 61.7 ± 12.7           | 61.7 ± 11.0                     | 0.981|
| BMI (kg/m\(^2\))                | 28.7 ± 7.1     | 28.6 ± 6.6            | 28.9 ± 8.4                      | 0.998|
| Comorbidities                   |                |                       |                                 |      |
| Diabetes mellitus               | 121 (82.9%)    | 87 (82.9%)            | 34 (82.9%)                      | 0.992|
| Peripheral vascular disease     | 117 (80.1%)    | 80 (76.2%)            | 37 (90.2%)                      | 0.866|
| Peripheral neuropathy           | 86 (58.9%)     | 65 (61.9%)            | 21 (51.2%)                      | 0.298|
| Active tobacco use              | 20 (13.7%)     | 15 (14.3%)            | 5 (12.2%)                       | 0.237|
| ESRD                            | 44 (30.1%)     | 28 (26.7%)            | 16 (39.0%)                      | 0.144|
| Charlson comorbidity index      | 5.7 ± 2.0      | 5.6 ± 2.0             | 5.9 ± 2.1                       | 0.484|
| Preoperative factors            |                |                       |                                 |      |
| Pre-albumin (mg/dL)             | 15.2 ± 6.8     | 15.5 ± 6.9            | 14.5 ± 6.7                      | 0.516|
| Albumin (g/dL)                  | 2.8 ± 0.7      | 2.9 ± 0.7             | 2.7 ± 0.7                       | 0.196|
| Hemoglobin A1c (%)              | 7.8 ± 2.4      | 7.7 ± 2.3             | 8.0 ± 2.8                       | 0.873|
| Acute osteomyelitis             | 81 (55.9%)     | 64 (61.0%)            | 17 (41.5%)                      | 0.033|
| Positive cultures on day of TMA| 101 (69.2%)    | 78 (74.3%)            | 28 (67.6%)                      | 0.946|
| LE Angiography                  | 42 (28.8%)     | 30 (28.6%)            | 12 (29.3%)                      | 0.910|
| One-vessel runoff               | 42 (28.8%)     | 29 (27.6%)            | 15 (31.7%)                      | 0.873|
| Two-vessel runoff               | 42 (28.8%)     | 32 (30.5%)            | 10 (24.4%)                      | 0.553|
| Three-vessel runoff             |                |                       |                                 |      |
| Endovascular intervention       | 80 (54.8%)     | 55 (52.4%)            | 24 (58.5%)                      | 0.553|

BMI, body mass index; ESRD, end-stage renal disease.

\( P \)-values in boldface signify statistical significance.
goal of a TMA is to provide a functional remaining foot that allows for reasonable weight-bearing and ambulation without a prosthesis. Yet, despite improvements in preoperative revascularization and medical optimization, TMA healing rates remain suboptimal and variable, with up to one-third of patients requiring proximal amputation.9 In this study, TMA success was achieved in 72% of patients, which parallels results of multiple other studies.12–15 The literature contains conflicting reports on individual patient and surgical factors that negatively impact TMA healing. Sheahan et al found that a revascularization procedure performed subsequent to partial foot amputation was a predictor of subsequent limb loss and advocated early revascularization to optimize healing of the TMA site.16 However, in this present study, preoperative revascularization was performed in similar proportions among those who experienced TMA success and those who required higher-level amputation. Poorly controlled hyperglycemia has also been associated with worse healing of TMA sites.17 Yet, hemoglobin A1c levels were similar between our two cohorts.

On multivariate analysis, we found postoperative infection to confer over a fourfold increase in odds of eventual proximal amputation. However, we did not find positive postdebridement cultures on day of TMA closure to be significantly associated with TMA failure. Results have been mixed in regard to the current literature on the effect of positive cultures on TMA healing. A recent study by Harris et

| Table 2. Perioperative Factors |
|-----------------------------|
| Variable                     | Total (n = 146) | TMA Success (n = 105) | Higher-level Amputation (n = 41) | P     |
| Open TMA                     | 41 (29.1%)     | 26 (24.8%)            | 15 (36.6%)                        | 0.153 |
| Closure types                | 67 (45.9%)     | 48 (45.7%)            | 19 (46.3%)                        | 0.946 |
| Primary closure              | 28 (19.2%)     | 22 (21.0%)            | 6 (14.6%)                         | 0.486 |
| Local flap                   | 23 (15.8%)     | 19 (18.1%)            | 4 (9.8%)                          | 0.312 |
| Free tissue transfer         | 21 (14.4%)     | 15 (14.3%)            | 6 (14.6%)                         | 1.000 |
| Delayed primary closure      |                |                      |                                   |       |
| Positive cultures on day of TMA closure | 101 (69.2%) | 72 (68.6%) | 29 (70.7%) | 0.946 |
| Additional procedures        | 69 (47.3%)     | 51 (48.6%)            | 18 (43.9%)                        | 0.612 |
| TAL                          | 4 (2.7%)       | 3 (2.9%)              | 1 (2.4%)                          | 1.000 |
| Gastrocnemius resection      |                |                      |                                   |       |
| Postoperative LOS (d)        | 14.7 ± 16.3    | 11.7 ± 11.6           | 22.5 ± 22.9                       | 0.002 |
| Antibiotics on discharge     | 20 (13.7%)     | 14 (13.3%)            | 6 (14.6%)                         | 0.403 |
| None                         | 88 (60.3%)     | 66 (62.9%)            | 22 (53.7%)                        |       |
| Oral                         | 28 (19.2%)     | 20 (19.0%)            | 8 (19.5%)                         |       |
| Parenteral                   | 10 (6.9%)      | 5 (4.8%)              | 5 (12.2%)                         |       |
| Oral and parenteral          |                |                      |                                   |       |

LOS, length of stay; TAL, tendon Achilles lengthening; P-values in boldface signify statistical significance.

| Table 3. Complications and Long-term Outcomes |
|----------------------------------------------|
| Variable                                    | Total (n = 146) | TMA success (n = 105) | Higher-level amputation (n = 41) | P     |
| Postoperative infection                     | 26 (17.8%)     | 10 (9.5%)             | 16 (39.0%)                        | <0.001 |
| Wound dehiscence                            | 65 (44.5%)     | 42 (40%)              | 23 (56.1%)                        | 0.079  |
| Unplanned return to operating room          | 62 (42.5%)     | 28 (26.7%)            | 34 (82.9%)                        | <0.001 |
| Hematoma                                    | 6 (4.1%)       | 4 (3.8%)              | 2 (4.9%)                          | 0.673  |
| Re-ulceration at TMA site                   | 55 (37.7%)     | 38 (36.2%)            | 17 (41.5%)                        | 0.556  |
| Higher-level amputation                      | 41 (28.1%)     | —                    | —                                 | —      |
| Lisfranc amputation                          | 13             | —                    | —                                 | —      |
| Chopart amputation                           | 9              | —                    | —                                 | —      |
| Below-knee amputation                        | 18             | —                    | 1.8 (0.6, 2.6)                    | —      |
| Median time to amputation (IQR; mo)          |                |                      | 23 (56.1%)                        | —      |
| Limb Salvage                                 | 128 (87.7%)    | 105 (100%)            | 23 (56.1%)                        | <0.001 |
| Ambulatory                                   | 121 (82.9%)    | 90 (85.7%)            | 31 (75.6%)                        | 0.145  |
| Decesed                                      | 43 (29.5%)     | 29 (27.6%)            | 14 (34.1%)                        | 0.437  |
| Follow-up duration (mo)                      | 25.2 ± 21.5    | 22.8 ± 22.1           | 24.2 ± 20.1                       | 0.496  |

IQR, interquartile range. P-values in boldface signify statistical significance.

| Table 4. Predictors of Secondary Proximal Amputation after Transmetatarsal Amputation |
|-----------------------------------------------|
| Variable                                      | Total Patients (n = 46) | TMA (n = 37) | Higher-level Amputation (n = 9) | P     |
| Time from surgery to survey completion (mo)   | 38.7 (30.3)             | —           | —                                 | —      |
| LEFS                                         | 47.1 (14.7)             | 49.1 (14.0) | 39.1 (15.7)                       | 0.068  |
| Percent maximal function                     | 58.9 (18.4)             | 61.3 (17.5) | 48.9 (19.6)                       | —      |

CI, confidence interval; PVD, peripheral vascular disease.
Deldar et al. • Outcomes after Transmetatarsal Amputation

Table 5. Lower Extremity Functional Scale Outcomes in Patients with Transmetatarsal Amputations

| Variable                        | Total Patients (n = 17) | TMA (n = 13) | Higher-level Amputation (n = 4) | P  |
|---------------------------------|------------------------|--------------|-------------------------------|----|
| Time from surgery to survey completion (mo) | 12.7 (13.9)          | --           | --                           | -- |
| PROMIS Pain interference*      | 52.5 (8.4)             | 53.6 (8.9)   | 49.0 (6.2)                    | 0.352 |
| Promis Pain intensity†         | 50.4 (10.7)            | 50.0 (11.9)  | 53.0 (6.4)                    | 0.591 |
| NRS‡                           | Current pain           | 1.8 (2.2)    | 1.1 (1.9)                     | 0.016 |
|                                | Best pain over 24 h    | 1.7 (2.1)    | 1.5 (2.1)                     | 0.562 |
|                                | Worst pain over 24 h   | 2.8 (2.5)    | 2.5 (2.7)                     | 0.382 |

Data are reported as mean (SD).

*PROMIS Pain Interference measures the extent that pain interferes with the ability to participate in social, cognitive, emotional, physical, and recreational activities over the past 7 days. T-scores range from 40.7 to 77, with higher scores indicating greater pain interference.
†PROMIS Pain Intensity measures current pain, average pain, and worst pain over the past 7 days. T-scores range from 36.5 to 81.8, with higher scores indicating greater pain intensity.
‡NRS rates pain on a scale of 0 (no pain) to 10 (worst pain).

with 70% in those unable to walk. The decision to perform primary BKA or TMA should be individualized to each patient depending on their comorbid status and functional goals. Active patients may not want to have the less predictable healing and revision surgery associated with a TMA and would rather undergo a BKA to return to their active lifestyle earlier with a custom-fitting prosthesis.

Patient-reported outcomes have become increasingly important as measures of treatment efficacy on patient symptoms and overall quality of life. The literature on the impact of surgical interventions on patient-reported outcomes within the chronic LE wound population is scarce. In this study, we found the overall LEFS score to correspond to 59% of maximal function. When stratified by TMA versus proximal amputation, patients with TMA success had a 12% higher maximal function compared with higher-level amputees. Moreover, the PROMIS pain surveys revealed the pain interference and intensity scores to be relatively equal among the two cohorts. The NRS pain survey, however, revealed that higher-level amputees had greater acute levels of pain within 24 hours compared with TMA only patients, with a significantly higher level of current pain. However, these patients may not have received our current protocol of indwelling peripheral nerve blocks and prophylactic targeted muscle reinnervation at the time of their higher-level amputation. This may have impacted their overall subjective pain scores. While our patient-reported outcomes are noteworthy, readers should not extrapolate our results into real-world practice until larger PROM studies are undertaken.

This study is limited by its retrospective nature, which relies on the quality of electronic medical records. We obtained mortality data solely from the electronic medical record; thus, the mortality rate may be underreported in this study. Furthermore, because of the tertiary referral nature of our practice, many patients come from long distances, and long-term follow-up of this population is often difficult to obtain. The heterogeneity among pre-TMA debridements, adjunctive procedures, and type of closures performed in our study population may have confounded our findings. In addition, the PROM surveys were not collected at the same time point for each patient, and the low response rates limit robust conclusions from being made. Nevertheless, this study contributes to the current foot and ankle literature and introduces...
patient-reported outcomes for patients with TMA versus higher-level amputees.

**CONCLUSIONS**

The variable healing rate and need for revision surgery following TMA should be discussed with patients to establish realistic postoperative expectations. Multi-institutional studies are warranted to identify perioperative risk factors for higher-level amputation and to further evaluate patient-reported outcomes.

Karen K. Evans, MD

MedStar Georgetown University Hospital
3800 Reservoir Road, NW
Washington, DC

E-mail: prsgeorgetownresearch@gmail.com

**REFERENCES**

1. Fitzgerald O’Connor EJ, Vesely M, Holt PJ, et al. A systematic review of free tissue transfer in the management of non-traumatic lower extremity wounds in patients with diabetes. *Eur J Vasc Endovasc Surg*. 2011;41:391–399.

2. Järbrink K, Ni G, Sörrennren H, et al. Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review. *Syst Rev*. 2016;5:152.

3. Nussbaum SR, Carter MJ, Fife CE, et al. An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. *Value Health*. 2018;21:27–32.

4. Wallace GF, Stapleton JJ. Transmetatarsal amputations. *Clin Podiatr Med Surg*. 2005;22:365–384.

5. Waters RL, Perry J, Antonelli D, et al. Energy cost of walking of amputees: the influence of level of amputation. *J Bone Joint Surg Am*. 1976;38:42–46.

6. Ahn J, Raspovic KM, Liu GT, et al. Renal function as a predictor of early transmetatarsal amputation failure. *Foot Ankle Spec*. 2019;12:439–451.

7. Adams BE, Edlinger JP, Ritterman Weintraub ML, et al. Three-year morbidity and mortality rates after nontraumatic transmetatarsal amputation. *J Foot Ankle Surg*. 2018;57:967–971.

8. Hosch J, Quiroga C, Bosma J, et al. Outcomes of transmetatarsal amputations in patients with diabetes mellitus. *J Foot Ankle Surg*. 1997;36:430–434.

9. Thorud JC, Jupiter DC, Lorenzana J, et al. Reoperation and reamputation after transmetatarsal amputation: a systematic review and meta-analysis. *J Foot Ankle Surg*. 2016;55:1007–1012.

10. Bosse MJ, MacKenzie EJ, Kellam JF, et al. An analysis of outcomes of reconstruction or amputation after leg-threatening injuries. *N Engl J Med*. 2002;347:1924–1931.

11. Bernard C. Transmetatarsal amputation. *Ortho Clin North Am*. 1973;4:31–42.

12. McKittrick LS, McKitrick JB, Risley TS. Transmetatarsal amputation for infection or gangrene in patients with diabetes mellitus. *Ann Surg*. 1949;130:826–840.

13. Blume P, Salonga C, Garbalos J, et al. Predictors for the healing of transmetatarsal amputations: retrospective study of 91 amputations. *Vascular*. 2007;15:126–133.

14. Toursarkissian B, Hagino RT, Khan K, et al. Healing of transmetatarsal amputation in the diabetic patient: is angiography predictive? *Ann Vasc Surg*. 2005;19:769–773.

15. Landry GJ, Silverman DA, Lien TK, et al. Predictors of healing and functional outcome following transmetatarsal amputations. *Arch Surg*. 2011;146:1005–1009.

16. Sheahan MG, Hamdan AD, Veraldi JR, et al. Lower extremity minor amputations: the roles of diabetes mellitus and timing of revascularization. *J Vasc Surg*. 2005;42:476–480.

17. Younger AS, Awwad MA, Kalla TP, et al. Risk factors for failure of transmetatarsal amputation in diabetic patients: a cohort study. *Foot Ankle Int*. 2009;30:1177–1182.

18. Harris RC III, Fang W. Transmetatarsal amputation outcomes when utilized to address foot gangrene and infection: a retrospective chart review. *J Foot Ankle Surg*. 2021;60:269–275.

19. Anway S, Nerone VS, Springer KD, et al. Rate of residual osteomyelitis after partial foot amputation in diabetic patients: a standardized method for evaluating bone margins with intraoperative culture. *J Foot Ankle Surg*. 2012;51:749–752.

20. Huang CT, Jackson JR, Moore NB, et al. Amputation: energy cost of amputation. *Arch Phys Med Rehabil*. 1979;60:18–24.

21. Serizawa F, Sasaki S, Fujishima S, et al. Mortality rate and walking ability transition after lower limb major amputation in hemodialysis patients. *J Vasc Surg*. 2016;64:1018–1025.

22. Wukich DK, Ahn J, Raspovic KM, et al. Comparison of transtibial amputations in diabetic patients with and without end-stage renal disease. *Foot Ankle Int*. 2017;38:388–396.

23. Quigley M, Dillon MP. Quality of life in persons with partial foot or transtibial amputation: a systematic review. *Prosthet Orthot Int*. 2016;40:18–30.

24. Singh RK, Prasad G. Long-term mortality after lower-limb amputation. *Prosthet Orthot Int*. 2016;40:545–551.

25. Hao SP, Houck JR, Waldman OV, et al. Prediction of post-interventional physical function in diabetic foot ulcer patients using patient reported outcome measurement information system (PROMIS). *Foot Ankle Surg*. 2021;27:224–230.

26. Chang BL, Mondshine J, Attinger CE, et al. Targeted muscle reinnervation improves pain and ambulation outcomes in highly comorbid amputees. *Plast Reconstr Surg*. 2021;148:376–386.